Lin Mei-Yi, Chiang Su-Yin, Li Yi-Zhen, Chen Mei-Fang, Chen Yueh-Sheng, Wu Jin-Yi, Liu Yi-Wen
Graduate Institute of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 404, Taiwan R.O.C.; Department of Chinese Medicine, Chiayi Christian Hospital, College of Life Sciences, National Chiayi University, Chiayi 600, Taiwan R.O.C.
Graduate Institute of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 404, Taiwan R.O.C.
Oncol Lett. 2016 Aug;12(2):904-910. doi: 10.3892/ol.2016.4698. Epub 2016 Jun 9.
Radix Paeoniae Rubra (RPR) is the dried root of Pallas and Lynch, and is a herbal medicine that is widely used in traditional Chinese medicine for the treatment of blood-heat and blood-stasis syndrome, similarly to Cortex Moutan. The present study identified the same three components in RPR and Cortex Moutan extracts. In addition, it has been reported that RPR has an anti-cancer effect. Bladder cancer is the seventh most common type of cancer worldwide. Due to the high recurrence rate, identifying novel drugs for bladder cancer therapy is essential. In the present study, RPR extract was evaluated as a bladder cancer therapy and . The present results revealed that RPR extract reduced the cell viability of bladder cancer cells with a half maximal inhibitory concentration of 1-3 mg/ml, and had an extremely low cytotoxic effect on normal urothelial cells. Additionally, RPR decreased certain cell cycle populations, predominantly cells in the G1 phase, and caused a clear sub-G increase. In a mouse orthotopic bladder tumor model, intravesical application of RPR extract decreased the bladder tumor size without altering the blood biochemical parameters of the mice. In summary, the present results demonstrate the anti-proliferative properties of RPR extract on bladder cancer cells, and its anti-bladder tumor effect . Compared to Cortex Moutan extract, RPR extract may provide a more effective alternative therapeutic strategy for the intravesical therapy of superficial bladder cancer.
赤芍是芍药科植物芍药及川赤芍的干燥根，是一种在传统中药中广泛用于治疗血热和血瘀证的草药，与牡丹皮类似。本研究在赤芍提取物和牡丹皮提取物中鉴定出了相同的三种成分。此外，据报道赤芍具有抗癌作用。膀胱癌是全球第七大常见癌症类型。由于复发率高，确定用于膀胱癌治疗的新药至关重要。在本研究中，对赤芍提取物作为膀胱癌治疗药物进行了评估。目前的结果显示，赤芍提取物可降低膀胱癌细胞的细胞活力，半数最大抑制浓度为1 - 3毫克/毫升，并且对正常尿路上皮细胞的细胞毒性极低。此外，赤芍减少了某些细胞周期群体，主要是G1期的细胞，并导致明显的亚G期增加。在小鼠原位膀胱肿瘤模型中，膀胱内应用赤芍提取物可减小膀胱肿瘤大小，而不改变小鼠的血液生化参数。总之，目前的结果证明了赤芍提取物对膀胱癌细胞的抗增殖特性及其抗膀胱肿瘤作用。与牡丹皮提取物相比，赤芍提取物可能为浅表性膀胱癌的膀胱内治疗提供更有效的替代治疗策略。
